Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis

Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasi

Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.

We tested the efficacy of 5-FU on secondary SCC in two melanoma patients who were being treated with the BRAF inhibitor dabrafenib (GSK2118436). We show that 5-FU provides a safe, noninvasive, inexpensive, and effective alternative to surgical intervention in clinical cases in which multiple surgeries are difficult or in cases in which lesions are incipient

Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes

Item does not contain fulltex

Erratum: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (Cancer Cell (2015) 27(1) (85–96) (S1535610814004577) (10.1016/j.ccell.2014.11.006))

(Cancer Cell 27, 85–96, January 12, 2015) The authors have noted an error in Figure 6A of the originally published version of this article. The image for pERK (top right panel) was incorrectly duplicated from Figure 4E (top right panel). The corrected Figure 6 is shown here. This error does not alter the original conclusions of the study, but the authors wish to apologize for this oversight and any confusion that may have resulted